FR2187305A1 - - Google Patents
Info
- Publication number
- FR2187305A1 FR2187305A1 FR7321732A FR7321732A FR2187305A1 FR 2187305 A1 FR2187305 A1 FR 2187305A1 FR 7321732 A FR7321732 A FR 7321732A FR 7321732 A FR7321732 A FR 7321732A FR 2187305 A1 FR2187305 A1 FR 2187305A1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/36—Methylene radicals, substituted by sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US262903A US3867380A (en) | 1971-02-18 | 1972-06-14 | 3-Heterocyclic thiomethylcephalosporins |
| US00289499A US3855213A (en) | 1971-02-18 | 1972-09-15 | 3-heterocyclic thiomethyl-cephalosporins |
| US35956773A | 1973-05-11 | 1973-05-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2187305A1 true FR2187305A1 (cg-RX-API-DMAC7.html) | 1974-01-18 |
| FR2187305B1 FR2187305B1 (cg-RX-API-DMAC7.html) | 1976-12-03 |
Family
ID=27401552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR7321732A Expired FR2187305B1 (cg-RX-API-DMAC7.html) | 1972-06-14 | 1973-06-14 |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS4949984A (cg-RX-API-DMAC7.html) |
| AU (1) | AU474443B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA999574A (cg-RX-API-DMAC7.html) |
| CH (1) | CH585228A5 (cg-RX-API-DMAC7.html) |
| DE (1) | DE2330307C2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES415874A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2187305B1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1416503A (cg-RX-API-DMAC7.html) |
| IE (1) | IE37793B1 (cg-RX-API-DMAC7.html) |
| NL (1) | NL7308199A (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215942A1 (cg-RX-API-DMAC7.html) * | 1973-01-31 | 1974-08-30 | Bristol Myers Co |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1074784A (en) * | 1974-09-06 | 1980-04-01 | Sumitomo Chemical Company | N-ACYLAMINO-.alpha.-ARYLACETAMIDO CEPHALOSPORINS |
| IL49183A0 (en) * | 1975-03-27 | 1976-05-31 | Pfizer | Novel cephalosporin derivatives,their preparation and pharmaceutical compositions containing them |
| JPS5346995A (en) * | 1976-10-12 | 1978-04-27 | Sangyo Kagaku Kenkyu Kyokai | Antibacterial agents |
| WO2010087425A1 (ja) | 2009-01-30 | 2010-08-05 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2042346A1 (cg-RX-API-DMAC7.html) * | 1969-04-18 | 1971-02-12 | Lilly Co Eli |
-
1973
- 1973-06-11 CA CA173,707A patent/CA999574A/en not_active Expired
- 1973-06-12 IE IE969/73A patent/IE37793B1/xx unknown
- 1973-06-12 GB GB2779473A patent/GB1416503A/en not_active Expired
- 1973-06-13 NL NL7308199A patent/NL7308199A/xx not_active Application Discontinuation
- 1973-06-13 ES ES415874A patent/ES415874A1/es not_active Expired
- 1973-06-13 CH CH852573A patent/CH585228A5/xx not_active IP Right Cessation
- 1973-06-14 AU AU56952/73A patent/AU474443B2/en not_active Expired
- 1973-06-14 FR FR7321732A patent/FR2187305B1/fr not_active Expired
- 1973-06-14 JP JP48067291A patent/JPS4949984A/ja active Pending
- 1973-06-14 DE DE2330307A patent/DE2330307C2/de not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2042346A1 (cg-RX-API-DMAC7.html) * | 1969-04-18 | 1971-02-12 | Lilly Co Eli |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215942A1 (cg-RX-API-DMAC7.html) * | 1973-01-31 | 1974-08-30 | Bristol Myers Co |
Also Published As
| Publication number | Publication date |
|---|---|
| IE37793L (en) | 1973-12-14 |
| GB1416503A (en) | 1975-12-03 |
| IE37793B1 (en) | 1977-10-12 |
| ES415874A1 (es) | 1976-02-01 |
| AU474443B2 (en) | 1976-07-22 |
| CH585228A5 (cg-RX-API-DMAC7.html) | 1977-02-28 |
| DE2330307C2 (de) | 1983-03-10 |
| DE2330307A1 (de) | 1974-01-03 |
| AU5695273A (en) | 1974-12-19 |
| JPS4949984A (cg-RX-API-DMAC7.html) | 1974-05-15 |
| FR2187305B1 (cg-RX-API-DMAC7.html) | 1976-12-03 |
| CA999574A (en) | 1976-11-09 |
| NL7308199A (cg-RX-API-DMAC7.html) | 1973-12-18 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |